|
Changing Medicine Together!
|
|
|
Tourette's Syndrome
|
Page Legend
|
|
|
Preferred Strain's
|
OG Kush
THC 16.00/20.00%
CBD 0.10/0.30% CBN -/-% THC/CBD Ratio 55/45% Sativa Dominant |
Blue Dream
THC 14.36/19.38%
CBD 1.05/1.77% CBN 0.51/2.66% THC/CBD Ratio 60/40% Sativa Dominant |
Critical Kush
THC 21.5/25.0%
CBD 0.01/0.32% CBN 0.01/1.00% THC/CBD Ratio 90/10% Indica Dominant |
Blue Cheese
THC 18.0/22.0%
CBD 0.8/1.8% CBN -/-% 80/20% Indica Dominant |
Dr. Who
THC 20.0/23.0%
CBD -/-% CBN -/-% THC/CBD Ratio 60/40% Indica Dominant |
|
Mendo Breath
THC 19.0/20.0%
CBD 0.10/0.60% CBN 0.01/0.03% 70/30% Indica Dominant |
Durban Poison
THC 15.0/25.0%
CBD 15.0/25.O% CBN -/-% THC/CBD Ratio 1:1 |
Super Silver Haze
THC 14.0/23.0%
CBD 14.0/23.0% CBN 1.0/2.0% THC/CBD Ratio 1:1 80/20% Sativa Dominant |
Sour Diesel
THC 21.50/27.00%
CBD 0.74/1.30% CBN 1.56/4.31% THC/CBD Ratio 90/10% Sativa Dominant |
Preferred Method to Medicate
|
+
+ + + (Under Tongue(Soft tissue)) + (Under Tongue(Soft tissue)) + |
|
|
Homeostasis
Cannabis Creates Homeostasis within the Bodies Regulatory Systems Homeostasis is Balance within the Body Cannabis regulates; Hormones, Lymph, Nervous System, Immune, & much more. |
CBS Minnesota
16 year old with severe Tourette's gets his life back
One drop of Cannabis Oil/Tincture every 2 hrs Josh went from hating his life to loving it! |
What is Tourette's Syndrome
Tourette Syndrome is a neuropsychiatric disorder, characterized by physical (motor) tics and vocal (phonic) tics. Motor or phonic tics are sudden, brief, intermittent, involuntary or semi-voluntary movements or sounds, respectively. They typically consist of brief, coordinated, repetitive movements, gestures, or utterances that mimic fragments of normal behavior. The tics associated with Tourette Syndrome can have significant effects on the academic and social development of children as well as affecting their overall self-esteem and mental health. Although the majority of children experience a decrease in their tics during adolescence, the worst symptoms are usually experienced by adults with intractable Tourette Syndrome.
|
MedicalMarijuana411.com
Cannabis, Changing Peoples Lives David Bearman, MD. Cannabis & Tourette's, ADHD/ADD, Movement Disorders, bi-Polar, & More, |
Tourette syndrome typically appears in children between 4 and 6 years old, two-thirds of them boys. But “about one-half to two-thirds of kids with Tourette’s get better in adolescence and we really don’t know why,” Bloch said. “You have involuntary movements or vocalizations that typically change in character over time.”
Fortunately, symptoms decrease as children get older. “Most times, since the tics are going to get better on their own … often the major treatment intervention would be just trying to minimize the impairment,” Bloch said, addressing problems the tics cause in school, at home or with friends. Bloch said that while about 80 percent of Tourette patients who smoke marijuana say it reduces the severity of their tics, more research is needed. The need for double-blind controlled studies was the reason the Board of Physicians did not allow those with Tourette to purchase medical marijuana, according to Dr. Cyril Deepak D’Souza, a member of the board who researched the issue in 2016 and found that no randomized clinical trials had been conducted on Tourette, |
Alzheimer’s disease or post-traumatic stress disorder. There is continuously, studies showing positive results, supporting Previous studies & the abundance of testimonials.
|
How Cannabis can Help Aid Tourette's
Tourette's syndrome is a disorder which has not yet been conclusively identified, although observation's and studies have suggested that the nervous system and/or more likely the brain is the system in which is suspected to be the area of origin. Scans conclusively show that subjects in question have abnormal/hyperactive assault if you will on the neurotransmitters, possibly caused by inflammation & excitotoxicity of the neurotransmitters, or the result of, compounding to the problem. this inflammation, if not the result of the ailment may not only cause the ailment but neuro-inflammatory problems also interfere with receptors such as the glutamate receptors but also cascade throughout ALL factions of the nervous system, eg. the central and peripheral nervous systems through to the autonomic nervous system, causing disfunction anywhere in the body.
Cannabis (Cannabiniods) Not only creates homeostasis/regulation throughout EVERY regulatory system in the body eg, brain, nervous system. immune, hormone, lymph, digestive, reproductive, etc. but as well regenerates cellular, bone, brain & muscle tissue, and Vitamin's & minerals, it's also Promotes Gene transcription modulation, it's a mineral transporter, enhancer, and on and on, Cannabis (Cannabiniods) cause more dopamine production as well, which facilitates retrograde inhibitions ( a way of modulating the speed of the neurotransmittion ). Cannabis then competes with dopamine for the dopamine binding sites on dopamine transporters. if enough cannabis/cannabinoids fill the bindings sites, the dopamine can't get in, resulting in more dopamine left for retrograde inhibition which results in a slower more controlled neurotransmittion and better ability to focus and successfully complete tasks. |
|
Laboratory Studies
1988 American Psychological Association, Marijuana & Tourette's Syndrome. Journal of Clinical Psychopharmacology
1998 Germany @ the Clinic for Psychiatry, Socialpsychiatry and Psychotherapy, led by Medical Scientist Kirsten Muller-Vahl
2001 Journal of the International Parkinson's and movement Disorder Society
Study Combined treatment of Tourette's Syndrome with Delta 9 THC & Dopamine receptors Antagonists
2007 - Study ~ Cannabinoids and neuroprotection in motor-related disorders.
Patents (There is a abundance of patents, here's a few related examples)
US6630507 A particular disclosed class of cannabinoids useful as neuroprotective antioxidants is formula (I) wherein the R group is independently selected from the group consisting of H, CH3, and COCH3.
WO1994012667A1 Nov 29, 1993Jun 9, 1994The United States Department Of The ArmyInhibitors of arachidonic acid metabolites for preventing neurological damage
For More Patents Check out Cannabis Patents and
For More Scientific Studies Check out the List's of;
> List's of Scientific Cannabis Studies
> List's of Endocannabiniod & Cannabis Studies
> List's of Delta 9-THC & Cannabis Studies
> List's of CBD & Cannabis Studies
1988 American Psychological Association, Marijuana & Tourette's Syndrome. Journal of Clinical Psychopharmacology
1998 Germany @ the Clinic for Psychiatry, Socialpsychiatry and Psychotherapy, led by Medical Scientist Kirsten Muller-Vahl
2001 Journal of the International Parkinson's and movement Disorder Society
Study Combined treatment of Tourette's Syndrome with Delta 9 THC & Dopamine receptors Antagonists
2007 - Study ~ Cannabinoids and neuroprotection in motor-related disorders.
Patents (There is a abundance of patents, here's a few related examples)
US6630507 A particular disclosed class of cannabinoids useful as neuroprotective antioxidants is formula (I) wherein the R group is independently selected from the group consisting of H, CH3, and COCH3.
WO1994012667A1 Nov 29, 1993Jun 9, 1994The United States Department Of The ArmyInhibitors of arachidonic acid metabolites for preventing neurological damage
For More Patents Check out Cannabis Patents and
For More Scientific Studies Check out the List's of;
> List's of Scientific Cannabis Studies
> List's of Endocannabiniod & Cannabis Studies
> List's of Delta 9-THC & Cannabis Studies
> List's of CBD & Cannabis Studies
2nd Phase Clinical Study
|
Therapix Biosciences and the Hannover Medical School Enter into an Investigator-initiated Clinical Trial Agreement to Assess the Effect of TXH-TS01 in Patients with Tourette SyndromeTEL AVIV, Israel, May 8, 2017 /PRNewswire/ — Therapix Biosciences Ltd. (Nasdaq: TRPX) (“Therapix”), a specialty clinical stage pharmaceutical company specializing in the development of cannabinoid-based drugs, today announced that it entered into a trial agreement with the Hannover Medical School to conduct a proof-of-concept Phase II clinical study with its lead compound, THX-TS01, for patients suffering from Tourette Syndrome.
As previously reported, this investigator initiated study, is projected to be initiated during the third quarter of 2017, subject to receiving necessary regulatory approvals in Germany. The study will be conducted at Hannover Medical School in Germany under the leadership of principal investigator, Professor Kirsten Muller-Vahl. The study will be a randomized, double-blind, placebo controlled cross-over proof-of-concept Phase II clinical study to evaluate the safety, tolerability and efficacy of up to twice daily oral THX-TS01 in treating adults with Tourette Syndrome (the “Hannover Study”). Each subject will be randomized to receive either THX-TS01 or placebo in a 1:1 ratio via oral administration. A total of 20 patients will be evaluated in a cross-over design. In the first stage, the patients will be randomized to either treatment or placebo and will be treated for a duration of 13 weeks. Afterwards, the patients will be crossed-over and will be treated for an additional 13 weeks; patients who initially received placebo will receive treatment and vice versa. The primary endpoint of the Hannover Study is to evaluate the safety, tolerance and efficacy of THX-TS01. The primary efficacy endpoint will be measured according to Yale Global Tic Severity Scale Total Tic Score, a widely-accepted index for assessing symptom severity and frequency. In addition, the effect of THX-TS01 will be evaluated by several secondary endpoints, including additional scales for measuring tics severity as well as other mental disorders that often accompany Tourette Syndrome, including OCD and ADHD. The therapeutic effect of THC in several CNS-related indications has long been established and my lab at Hannover Medical Schools feels fortunate to have been centrally involved in that research. 
Professor Kirsten Muller-Vahl, department of Psychiatry, Socialpsychiatry and Psychotherapy and head of the Tourette outpatient clinic at Hannover Medical School
Professor Muller-Vahl continued, “This robust study that we are embarking upon with Therapix Biosciences will assess the potential synergistic effect of THC in combination with PEA, in what my esteemed colleague Professor Raphael Mechoulam coined the ‘Entourage Effect’ many years ago. We’re enthusiastic to be conducting this study, and optimistic about its findings,” concluded Professor Muller-Vahl.
|
Benefits of Cannabis CBD
Neuro-inflammatory Disorder Science of Cannabis Delivery system, usage, & Mechanism in Neuro-inflammatory disorders. Yale Professor Studies Cannabis & Tourette's
While the Board of Physicians for the state Department of Consumer Protection’s medical marijuana program rejected Tourette syndrome as an approved condition, researchers are studying the properties in cannabis that appear to help relieve the tics that come with the disorder, according to Dr. Michael Bloch, an associate professor at the Yale Child Study Center and assistant director of the center’s Tic Disorder/Obsessive Compulsive Disorder Specialty Clinic.
Cannabis talk
Dr. Mercola and Dr.Gedde Mixed cannabis information |
We’re excited to embark upon the Hannover Study. Hannover Medical School is well regarded as a center of excellence in this area of research, and Professor Muller-Vahl is a recognized key opinion leader in both cannabinoid-based therapeutics and Tourette Syndrome.
Dr. Elran Haber, Therapix’s Chief Executive Officer
We’re optimistic that the Hannover Study, in conjunction with our currently ongoing study at Yale University, will support earlier research done with cannabinoid-based therapies and may suggest that THX-TS01 is a safe and efficacious treatment for this highly debilitating disease with high unmet medical need.
Therapix Biosciences Ltd.
is a specialty clinical-stage pharmaceutical company led by an experienced team of senior executives and scientists, focused on creating and enhancing a portfolio of technologies and assets based on cannabinoid pharmaceuticals. With this focus, the company is currently engaged in two internal drug development programs based on repurposing an FDA approved synthetic cannabinoid (dronabinol): THX-TS01 targets to the treatment of Tourette’s syndrome; and THX-ULD01 targets the high-value and under-served market of mild cognitive impairments. Please visit our website for more information at www.therapixbio.com.
is a specialty clinical-stage pharmaceutical company led by an experienced team of senior executives and scientists, focused on creating and enhancing a portfolio of technologies and assets based on cannabinoid pharmaceuticals. With this focus, the company is currently engaged in two internal drug development programs based on repurposing an FDA approved synthetic cannabinoid (dronabinol): THX-TS01 targets to the treatment of Tourette’s syndrome; and THX-ULD01 targets the high-value and under-served market of mild cognitive impairments. Please visit our website for more information at www.therapixbio.com.
About THX-TS01:
THX-TS01 is a combination drug candidate for the treatment of Tourette Syndrome and it is based on two components: (1) dronabinol, the active ingredient in an FDA approved synthetic analog of tetrahydrocannabinol (“THC”), which is the psychoactive molecule in the cannabis plant, and (2) Palmitoylethanolamide (“PEA”), which is an endogenous fatty acid amide that belongs to the class of nuclear factor agonists, which are proteins that regulate the expression of genes. The combination of THC and PEA may induce a reaction known as the “entourage effect.” The basic tenet of the entourage effect is that cannabinoids work together, or possess synergy, and affect the body in a mechanism similar to the body’s own cannabinoid system, which is a group of molecules and receptors in the brain that mediates the psychoactive effects of cannabis. This entourage effect may account for the pharmacological actions of PEA. Based on an activity enhancement of other physiological compounds, PEA may indirectly stimulate the cannabinoid receptors by potentiating their affinity for a receptor or by inhibiting their metabolic degradation, and by doing so, may increase the uptake of cannabinoid compounds, such as THC. Thus, it is speculated that the presence of the PEA molecule likely increases the efficacy of orally administered THC, while reducing the required dosage and decreasing associated deleterious adverse events.
THX-TS01 is a combination drug candidate for the treatment of Tourette Syndrome and it is based on two components: (1) dronabinol, the active ingredient in an FDA approved synthetic analog of tetrahydrocannabinol (“THC”), which is the psychoactive molecule in the cannabis plant, and (2) Palmitoylethanolamide (“PEA”), which is an endogenous fatty acid amide that belongs to the class of nuclear factor agonists, which are proteins that regulate the expression of genes. The combination of THC and PEA may induce a reaction known as the “entourage effect.” The basic tenet of the entourage effect is that cannabinoids work together, or possess synergy, and affect the body in a mechanism similar to the body’s own cannabinoid system, which is a group of molecules and receptors in the brain that mediates the psychoactive effects of cannabis. This entourage effect may account for the pharmacological actions of PEA. Based on an activity enhancement of other physiological compounds, PEA may indirectly stimulate the cannabinoid receptors by potentiating their affinity for a receptor or by inhibiting their metabolic degradation, and by doing so, may increase the uptake of cannabinoid compounds, such as THC. Thus, it is speculated that the presence of the PEA molecule likely increases the efficacy of orally administered THC, while reducing the required dosage and decreasing associated deleterious adverse events.
Note: The fact that they are re-creating the cannabis molecule's suggests cannabis works as well as all the studies and patents.
Remember nature is you, and you are not synthetic. the natural plant (Nature is always better & safer).
Check out the Studies; Single Molecule vs Hole Plant & Entorauge Effect & Terpenes
Remember nature is you, and you are not synthetic. the natural plant (Nature is always better & safer).
Check out the Studies; Single Molecule vs Hole Plant & Entorauge Effect & Terpenes
